<div id="readability-page-1"><div><p>As the U.S. stock market grapples with pressures on AI stocks and anticipates key economic data releases, investors are keenly observing how these factors influence broader market trends. In such a volatile environment, growth companies with high insider ownership often stand out as they suggest confidence from those closest to the business, making them intriguing prospects for investors seeking stability amid uncertainty.</p><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3><table><tbody><tr><td><strong>Name</strong></td><td><strong>Insider Ownership</strong></td><td><strong>Earnings Growth</strong></td></tr><tr><td>Super Micro Computer (SMCI)</td><td>13.9%</td><td>50.7%</td></tr><tr><td>StubHub Holdings (STUB)</td><td>14.2%</td><td>73.9%</td></tr><tr><td>SES AI (SES)</td><td>12%</td><td>68.9%</td></tr><tr><td>Niu Technologies (NIU)</td><td>37.2%</td><td>93.7%</td></tr><tr><td>Karman Holdings (KRMN)</td><td>17.3%</td><td>78.5%</td></tr><tr><td>Credo Technology Group Holding (CRDO)</td><td>10.4%</td><td>30.7%</td></tr><tr><td>Corcept Therapeutics (CORT)</td><td>11.4%</td><td>52.7%</td></tr><tr><td>Atour Lifestyle Holdings (ATAT)</td><td>18%</td><td>24.4%</td></tr><tr><td>Astera Labs (ALAB)</td><td>11.7%</td><td>29.0%</td></tr><tr><td>AppLovin (APP)</td><td>27.4%</td><td>27.1%</td></tr></tbody></table><p>Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p><p>Let's dive into some prime choices out of the screener.</p><h2>Paysign (PAYS)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Paysign, Inc. offers prepaid card programs, patient affordability solutions, digital banking services, and integrated payment processing for various sectors with a market cap of $295.03 million.</p><p><strong>Operations:</strong> Paysign's revenue primarily comes from its vertically integrated provider of prepaid card products and processing services, generating $74.88 million.</p><p><strong>Insider Ownership:</strong> 36.3%</p><p><strong>Earnings Growth Forecast:</strong> 25.4% p.a.</p><p>Paysign's growth trajectory is underscored by a forecasted earnings increase of 25.42% per year, outpacing the US market's 16.1%. Despite revenue growth being slower than 20%, it surpasses the market average at 18.4%. Recent quarterly results show significant year-over-year improvements in sales and net income, with full-year revenues projected to grow by nearly 39%. The company's strategic leadership changes aim to enhance its life sciences sector presence, though insider trading activity remains minimal.</p><ul><li>Get an in-depth perspective on Paysign's performance by reading our analyst estimates report here.</li><li>The valuation report we've compiled suggests that Paysign's current price could be inflated.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth"/><figcaption>PAYS Earnings and Revenue Growth as at Dec 2025</figcaption></figure><h2>Amneal Pharmaceuticals (AMRX)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide with a market cap of approximately $3.92 billion.</p><p><strong>Operations:</strong> The company's revenue segments include Avkare at $704.37 million, Specialty at $482.42 million, and Affordable Medicines at $1.75 billion.</p><p><strong>Insider Ownership:</strong> 39.2%</p><p><strong>Earnings Growth Forecast:</strong> 80.1% p.a.</p><p>Amneal Pharmaceuticals shows potential as a growth company with significant insider ownership, highlighted by its recent FDA approvals for key products like epinephrine injections and albuterol sulfate inhalation aerosol, adding to its expanding respiratory portfolio. While trading at a good value compared to peers, the company's earnings are expected to grow significantly over the next three years, despite revenue growth forecasts lagging behind the broader market. The company's strategic moves in complex drug formulations underscore its commitment to innovation.</p><ul><li>Click here and access our complete growth analysis report to understand the dynamics of Amneal Pharmaceuticals.</li><li>Our comprehensive valuation report raises the possibility that Amneal Pharmaceuticals is priced lower than what may be justified by its financials.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth"/><figcaption>AMRX Earnings and Revenue Growth as at Dec 2025</figcaption></figure><h2>Dingdong (Cayman) (DDL)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Dingdong (Cayman) Limited operates as an e-commerce company in China with a market cap of approximately $439.33 million.</p><p><strong>Operations:</strong> The company generates revenue primarily through its online retail segment, which reported CN¥24.02 billion.</p><p><strong>Insider Ownership:</strong> 28.6%</p><p><strong>Earnings Growth Forecast:</strong> 25% p.a.</p><p>Dingdong (Cayman) demonstrates growth potential with substantial insider ownership, trading at a good value compared to peers. Despite revenue growth forecasts of 9.1% per year lagging behind the US market, its earnings are expected to grow significantly at 25% annually over the next three years. Recent Q3 results showed increased revenue but decreased net income and earnings per share, reflecting challenges in maintaining profitability amidst expansion efforts.</p><ul><li>Click to explore a detailed breakdown of our findings in Dingdong (Cayman)'s earnings growth report.</li><li>Our valuation report unveils the possibility Dingdong (Cayman)'s shares may be trading at a discount.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown"/><figcaption>DDL Ownership Breakdown as at Dec 2025</figcaption></figure><h2>Taking Advantage</h2><ul><li>Click through to start exploring the rest of the 201  Fast Growing US Companies With High Insider Ownership now.</li><li>Looking For Alternative Opportunities? We've found 13 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders.      It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities.      All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

AMRX

<p>Investors are closely monitoring growth companies with high insider ownership amid market volatility. Notable companies include Super Micro Computer, StubHub Holdings, SES AI, Niu Technologies, Karman Holdings, Credo Technology, Corcept Therapeutics, Atour Lifestyle, Astera Labs, and AppLovin. Highlighted companies are Paysign, Amneal Pharmaceuticals, and Dingdong (Cayman), each showing significant insider ownership and promising earnings growth forecasts. Simply Wall St provides detailed analysis but advises that their commentary is not financial advice.</p>

Three Insider-Favored Growth Companies To Watch